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ABSTRACT
Psoriasis is a lifelong disease associated with
cycles of remission and relapse. Topical treatments are the front line of psoriasis therapy for
most patients and have antiproliferative, antiinflammatory, and immunosuppressive mechanisms of action. Novel fixed-dose combinations
of topical therapeutic agents are becoming
increasingly available, leveraging multiple
mechanisms of action to improve safety and
efficacy with formulations that are easier to use
and may allow for the use of lower doses of
active ingredients. A fixed-combination lotion
containing the potent-to-superpotent corticosteroid halobetasol propionate (HP) and the
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retinoid tazarotene (HP 0.01%/TAZ 0.045%) was
recently developed using polymeric emulsion
technology. This new formulation technology
allows for more uniform and efficient delivery
of the active ingredients at lower doses than
conventional monotherapy formulations of
either ingredient while providing enhanced
hydration and moisturization. This review provides an up-to-date overview of the therapeutic
mechanisms of action of HP and TAZ, the
rationale behind the development of HP 0.01%/
TAZ 0.045% lotion, and clinical trials data on
the efficacy, safety and tolerability, and maintenance of therapeutic effect with HP 0.01%/
TAZ 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis.

Keywords: Corticosteroid; Duobrii; Efficacy;
Formulation; Halobetasol propionate; Lotion;
Psoriasis; Retinoid; Safety; Tazarotene
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Key Summary Points
Topical therapies are widely used for the
treatment for psoriasis; combination
therapies utilizing more than one topical
agent may provide greater efficacy, safety,
and tolerability.
The corticosteroid halobetasol propionate
(HP) and retinoid tazarotene (TAZ) are
commonly used topical therapies that
address the pathophysiology of psoriasis
through complementary mechanisms of
action.
A fixed-combination HP 0.01%/TAZ
0.045% lotion was developed to
simultaneously deliver the two active
ingredients and moisturizing excipients in
a single formulation.
HP 0.01%/TAZ 0.045% lotion has
demonstrated improved efficacy, safety,
tolerability, and maintenance of
therapeutic effect compared to
monotherapy with either active
ingredient.

DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate understanding of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.14662191.

INTRODUCTION
Psoriasis is a chronic inflammatory skin disorder
associated with abnormal differentiation and
hyperproliferation of keratinocytes, dermal
infiltration of immune cells, increased vascularization, and breakdown of the epidermal
barrier, resulting in raised, erythematous, scaly
plaques [1–3]. Approximately 80% of patients
with psoriasis have mild to moderate disease,

for which topical therapy is commonly used as
an integral component of treatment [4, 5].
Topical therapies are also widely used by
patients with severe disease, as many do not
achieve complete clearance with systemic therapies; the residual psoriasis in these patients can
be managed successfully through the addition
of topical therapy [6]. Among the most commonly used topical therapies for psoriasis are
topical corticosteroids (TCS), vitamin D analogues, and the retinoid tazarotene (TAZ) [7].
These treatments are available in a variety of
formulations and address the pathophysiology
of
psoriasis
through
anti-inflammatory,
antiproliferative,
immunosuppressive,
and
vasoconstrictive
mechanisms
of
action
[5, 8–10].
Although these topical therapies are efficacious in the treatment of psoriasis, their longterm use is limited by safety concerns. Prolonged TCS use is associated with adverse cutaneous reactions, tachyphylaxis, and rebound
effects upon sudden cessation of treatment
[9, 11]; given these safety concerns, package
inserts recommend no more than 2–4 weeks of
continuous TCS usage [11]. TAZ has been shown
to be equally efficacious as TCS while providing
longer duration of effect posttreatment [12], but
may be underutilized because of local irritation
in lesional and perilesional skin [4]; vitamin D
analogues have likewise been associated with
local skin reactions [5]. Some newer treatments
have combined corticosteroids with a second
ingredient, such as TAZ or a vitamin D analogue, to potentially reduce adverse events (AEs)
and improve efficacy [7]. For example, TAZ used
together with a mid- or high-potency TCS is
more effective in the treatment of psoriasis than
TAZ monotherapy, is associated with fewer
safety concerns than monotherapy with either
active ingredient, and is recommended for the
treatment of mild to moderate psoriasis [5].
Additionally, TAZ increases the duration of TCS
treatment effect and the duration of psoriasis
remission [5].
The need for new topical psoriasis therapies
that provide improved efficacy and increased
duration of remission after treatment cessation,
while maintaining a favorable tolerability and
safety profile, cannot be understated. In a recent
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patient survey, almost half of respondents
reported being ‘‘not very’’ or ‘‘not at all’’ satisfied
with their current plaque psoriasis treatment; of
these, three-quarters cited a lack of effectiveness
as the reason for their treatment dissatisfaction,
with an additional 10% expressing concerns
about side effects and safety. Moreover, of those
who had previously used a topical therapy and
were currently using a biologic or systemic
therapy, over half stated that they would have
continued using the topical therapy had it been
more effective [13]. Although the concurrent
use of two topical therapies can provide
improved outcomes over monotherapy, practical and technical challenges persist for therapies
that include multiple active ingredients. For
example, layering medications can decrease
their permeability [14] and the need to apply
multiple medications can complicate adherence
[7].
Recently, a fixed-combination lotion containing the potent-to-superpotent corticosteroid halobetasol propionate (HP) and
tazarotene (HP 0.01%/TAZ 0.045%; DuobriiÒ;
Ortho Dermatologics, Bridgewater, NJ, USA)
was developed to meet the need for an efficacious topical psoriasis therapy with fewer safety
concerns and improved duration of effect
compared to monotherapy with either active
ingredient [14]. This novel lotion formulation
utilizes an innovative polymeric emulsion
technology to provide uniform and simultaneous delivery of active ingredients at lower doses
than conventional monotherapy formulations
while providing enhanced hydration and
moisturization.
In this review, the rationale behind the
development of HP 0.01%/TAZ 0.045% lotion is
discussed, beginning with the mechanisms of
action of TAZ and HP in psoriasis. The HP
0.01%/TAZ 0.045% lotion formulation is
described, and data are presented demonstrating improved penetration of the active ingredients compared to conventional formulations
used alone or in layers, and benefits to epidermal barrier function. Finally, efficacy and safety
data from clinical trials of HP 0.01%/TAZ
0.045% lotion for the treatment of psoriasis are
reviewed, highlighting how the complementary
mechanisms of action of the active ingredients

improve efficacy, maintenance of treatment
effects, and safety. All clinical trials data presented here are from previously conducted
studies; this article does not contain any new
studies with human participants or animals
performed by any of the authors.

TAZ AND HP: MECHANISMS
OF ACTION IN PSORIASIS
TAZ Mechanisms of Action
Approved over 20 years ago, TAZ is the first
topical retinoid that was developed for the
treatment of psoriasis [15]. It is a retinoid prodrug that is rapidly metabolized to tazarotenic
acid, which acts as a high-affinity ligand for
retinoic acid receptors (RAR) b and c while
remaining inactive at RARa and retinoid X
receptors [15]. This receptor selectivity may
contribute to the therapeutic effects of TAZ in
psoriasis, as RARc accounts for 90% of all RARs
and is the RAR primarily found in the skin [16].
RARs serve as ligand-dependent transcription
factors that can regulate the expression of psoriasis-associated genes in two ways: by binding
directly to those genes’ promotor sites or by
modulating the activity of intermediary signaling pathways [15–17]. Through these two
mechanisms, TAZ modulates keratinocyte proliferation and differentiation, downregulates
pro-inflammatory mechanisms, and reduces
immune cell recruitment (Fig. 1). As such,
treatment with TAZ is thought to return skin to
a quiescent, ‘‘prelesional’’ state [15].
Regulation of Cell Proliferation
and Differentiation
Upon activation by tazarotenic acid, RARs
directly upregulate the expression of three
genes, dubbed tazarotene-induced genes (TIG1,
TIG2, and TIG3). TIG1 is believed to code for a
cell adhesion molecule or surface receptor that
regulates cell proliferation and differentiation
in a variety of tissues [18]. In a clinical study,
response to TAZ treatment was associated with
increased TIG1 expression in psoriatic lesional
tissue [16]. TIG3 is a putative tumor suppressor
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Fig. 1 Tazarotene mechanisms of action in psoriasis. TAZ
is a retinoid prodrug that is rapidly metabolized to TA,
which binds selectively to RAR b and c. Activated RARs
address the pathogenic factors in psoriasis both directly (by
acting as transcription factors for TIG1, 2, and 3) and
indirectly (e.g., by modulating the expression or transcriptional activity of other factors, such as AP-1). AP activator
protein family, EGFR epidermal growth factor receptor,
HLA human lymphocyte antigen, ICAM intercellular
adhesion molecule, IFN interferon, IL interleukin, K
keratin, MRP migration inhibitory factor-related protein,
ODC ornithine decarboxylase, RAR retinoic acid receptor,
SKALP skin-derived antileukoproteinase, TA tazarotenic
acid, TAZ tazarotene, TGase K keratinocyte transglutaminase, TIG tazarotene-induced gene, TNF tumor necrosis
factor
that also appears to be particularly important
for the terminal differentiation of keratinocytes
[19]; its activity is downregulated in epidermal
hyperproliferative diseases such as psoriasis and
skin cancer [20]. Though TIG2 may have
antiproliferative effects [16], it also contributes
to immune cell recruitment and inflammatory
processes (discussed below). In psoriatic lesional
tissue, expression of all three TIGs is low, and is
upregulated by treatment with TAZ [16].
In addition to directly modulating gene
expression, TAZ-induced RAR activation can
indirectly modulate processes underlying keratinocyte proliferation and differentiation in
psoriatic lesions [16, 21]. TAZ-activated RARs
inhibit dimerization of proteins in the activator

protein 1 (AP-1) family of transcription factor
complexes [22]. Blocking dimerization prevents
AP-1 from driving the expression of genes for
many cytokines—including tumor necrosis factor alpha (TNFa), interleukin (IL)-4, and interferon-c (IFNc)—that are secreted by activated
immune cells and infiltrating T cells and that
promote
keratinocyte
hyperproliferation
[23–26]. In patients with psoriasis, genes enriched in lesional versus nonlesional tissue were
associated with AP-1 binding sites and cytokine
induction [27]. In preclinical findings, TAZ
antagonized AP-1-dependent gene expression
[28]; such downregulation of AP-1 activity has
been associated with amelioration of psoriasislike lesions [29]. In addition to its effects on
cytokine production, TAZ antagonizes AP-1mediated expression of ornithine decarboxylase, a key regulator of the synthesis of
polyamines that are required for cell proliferation [28].
TAZ-activated RARs can also normalize the
expression of epidermal growth factor receptors
(EGFR), which directly stimulate growth and
differentiation in many epithelial tissues and
are overexpressed in psoriatic perilesional skin
[30]. Alterations in EGFR cause abnormal cell
proliferation and may cause human skin disease
[30, 31]. Conversely, reduction in EGFR is one
of the first detectable changes that occurs with
many treatments for psoriasis; these receptors
begin to disappear as the skin normalizes and
parakeratosis begins to resolve [30]. In patients
with psoriasis, 2 weeks of TAZ treatment was
associated with reduced EGFR expression [32].
TAZ has demonstrated the ability to reverse
over- and underexpression of many other
markers of keratinocyte differentiation and cell
proliferation in psoriatic lesional tissue,
including: filaggrin, involucrin, and keratins
(e.g., K6, 10, and 16), which are structural proteins underlying the cornified envelope; migration inhibitory factor-related protein 8 (MRP-8,
aka protein S100-A8), which binds to keratin
filaments and associates with the epidermal
cytoskeleton; keratinocyte transglutaminase
type I (TGase K), which catalyzes the assembly
of the cornified envelope; and skin-derived
antileukoproteinase (SKALP), a protease/elastase
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inhibitor (reviewed in Duvic et al., 1997; 1998;
Lee, 2020) [16, 21, 33].
Downregulation of Inflammation Markers
and Reduced Immune Cell Recruitment
Psoriatic lesions arise in part from immune
cells, local skin cells, and cytokines interacting
to create a pro-inflammatory environment that
promotes keratinocyte proliferation. In keratinocytes, TNFa and IFNc induce the expression of intracellular adhesion molecule-1
(ICAM-1); IFNc also induces expression of
human lymphocyte antigens DR (HLA-DR) [34].
ICAM-1 expression is particularly correlated
with the degree of dermal inflammation [34],
whereas HLA-DR expression correlates with
psoriasis severity [21]. These cell surface antigens are increased in untreated psoriatic skin
compared to nonlesional or normal skin and
may recruit T cells to the epidermis in psoriasis
[16, 21, 34]. In clinical studies, TAZ treatment
decreased levels of ICAM-1 and HLA-DR in
patients with psoriasis [32] and decreased dermal infiltration of leukocytes (e.g., CD45?
T cells) in patients with T cell lymphoma [35].
As noted above, TAZ downregulates the
expression of MRP-8 [16], the production and
secretion of which is stimulated by TNFa. In
addition to its role in cell proliferation/differentiation, MRP-8 recruits leukocytes to inflammation sites, further stimulating the expression
of TNFa, IL-6, and other pro-inflammatory
cytokines—thus creating a positive feedback
loop for epidermal inflammation [36, 37].
Additionally,
TAZ
regulates
immune
responses and inflammation in psoriasis by
upregulating the expression of TIG2, which is
hypothesized to play a role in maintaining the
normal physiology of skin [16, 38]. The protein
product of TIG2, chemerin, plays a complex
role in immune and inflammatory processes. In
early stages of inflammation, chemerin coordinates pro-inflammatory immune responses
such as the trafficking of plasmacytoid dendritic
cells (DCs) to the site of inflammation [39, 40].
These DCs are among the most abundant sources of the cytokine IFNa, which stimulates the
maturation of immune cells and the production
of many other cytokines; thus, activation of
DCs may represent an early step in psoriasis

pathogenesis [41]. Consistent with this, chemerin levels are elevated in new, evolving psoriatic plaques and in pre-lesional dermis relative
to normal or uninvolved skin [41]. In contrast,
at the end of inflammation, chemerin transforms to play an anti-inflammatory role [40].
Consequently, in chronic, non-evolving psoriatic lesions, chemerin expression in the epidermis may favor the clearance of immune cells
from inflamed tissue and the restoration of skin
homeostasis [42]. Thus, upregulation of TIG2
expression in chronic psoriatic lesions by TAZ
may support the anti-immune and anti-inflammatory mechanisms of chemerin.
HP Mechanisms of Action
Corticosteroids such as HP have been used in
dermatology for over 50 years and their physiological effects have been reviewed extensively
[9, 43, 44]. They impact the pathophysiology of
psoriasis via activation of glucocorticoid

Fig. 2 Halobetasol propionate mechanisms of action in
psoriasis. HP is a synthetic glucocorticoid that binds
directly to GR. Activated GR can exert both genomic (e.g.,
upregulation of lipocortin synthesis) and non-genomic
(e.g., suppression of pro-inﬂammatory cytokines) effects to
address the pathophysiology of psoriasis. AP activator
protein, GR glucocorticoid receptor, HP halobetasol
propionate, ICAM intercellular adhesion molecule, IL
interleukin, IFN interferon, NF-jB nuclear factor kappalight-chain-enhancer of activated B cells, NO nitric oxide,
TNF tumor necrosis factor
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receptors (GR) which, like activated RARs, exert
both genomic and non-genomic actions to
regulate transcription of genes for anti-inflammatory and pro-inflammatory mediators (e.g.,
IL-6, NF-jB, and TNFa; Fig. 2) [43]. HP-induced
GR activation decreases activity of AP-1 proteins, though through a different pathway than
TAZ-induced RARs; whereas activated RARs
prevent the dimerization of AP-1 proteins,
activated GRs reduce their phosphorylation [9].
GR-mediated stimulation of lipocortin synthesis leads to decreased conversion of cell membrane phospholipids into pro-inflammatory
arachidonic acid [45]. In addition, activation of
GRs inhibits the expression and activity of
many other cytokines and chemokines that
traffic pro-inflammatory mediators to the site of
inflammation (reviewed in Barnes 1998; Uva
et al. 2012) [9, 43].
Corticosteroids also mitigate vascular, cell
proliferation, and immunological features of
psoriasis, though the mechanisms underlying
these effects are not as well understood. GR
activation inhibits prostaglandin formation and
mitigates inflammation-induced nitric oxide
synthesis [46, 47], thus causing vasoconstriction
and reducing the delivery of pro-inflammatory
mediators to areas treated with TCS [9]. However, tachyphylaxis to prolonged TCS use may
occur as a result of the loss of vasoconstriction
at the level of capillaries [48]. In addition to
effects on inflammation, lipocortin upregulation by corticosteroids may regulate keratinocyte hyperproliferation by inhibiting
epidermal mitosis [9]. Corticosteroids also
repress the maturation, differentiation, and
proliferation of immune cells, leading to
reduced production of pro-inflammatory mediators [9]. The antiproliferative mechanisms of
corticosteroids may contribute to their atrophogenic potential. In addition to reduced
keratinocyte proliferation [9], fibroblast proliferation is suppressed, and there is decreased
production of mucopolysaccharides (e.g., hyaluronic acid), elastin, matrix metalloproteases,
and collagen 1 and 3. Mast cell numbers are
reduced, dermal support is lost, and skin
becomes thinned and loses elasticity [49].

HP 0.01%/TAZ 0.045% LOTION
FORMULATION
Benefits of Concurrent Use of TAZ and TCS
Psoriasis therapies employing both TAZ and a
TCS have demonstrated improved efficacy over
monotherapy with either treatment. In one of
the first studies to evaluate the efficacy of TAZ
used in combination with a TCS, the time to
initial treatment success was reduced from
4 weeks with TAZ monotherapy to 2 weeks with
TAZ plus mometasone furoate. Moreover, the
percentages of participants achieving treatment
success and reductions in body surface area
(BSA) involvement were significantly greater
with the combination therapy [50]. Similarly, a
separate study found that TAZ plus mometasone furoate yielded greater and more rapid
improvements in psoriasis than mometasone
furoate monotherapy. Moreover, combination
therapy yielded greater duration of posttreatment maintenance of effects and decreased
discontinuations due to posttreatment disease
recurrence [51]. The enhanced efficacy of TAZ
and TCS when used together may reflect their
complementary mechanisms of action, including distinct processes by which they regulate
hyperproliferation (e.g., filaggrin upregulation
by TAZ and lipocortin upregulation by TCS) and
inflammation (e.g., non-overlapping mechanisms of AP-1 inhibition). Posttreatment maintenance of therapeutic effect may be due to
normalization of gene expression in lesional
skin by TAZ.
When used together, TAZ and TCS can also
mitigate the safety and tolerability concerns
associated with use of either as monotherapy, as
evidenced by low incidences of AEs and steroid
rebound in clinical trials [52]. Safety concerns
with TAZ include application site pain, itching,
and swelling; in preclinical studies, these effects
were blocked by antagonism or ablation of the
irritant receptor TRPV1, suggesting a mechanism underlying these side effects [53]. GR
activation enhances the degradation of TRPV1
[54], thus providing a means by which TCS may
mitigate TAZ-induced irritation. Erythema,
another common local skin reaction to TAZ,
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may be lessened by the vasoconstrictive effects
of TCS. One of the greatest concerns with prolonged TCS use is skin atrophy, caused in part
by decreased collagen synthesis and inhibition
of cell proliferation [44]. In treatment of psoriatic perilesional skin, addition of a retinoid to
TCS therapy partially protected against TCS-induced epidermal atrophy [55]. TAZ has been
shown to increase epidermal thickness in photodamaged skin [56] and to reduce TCS-induced
atrophy in healthy skin [57]. Thus, combination
of TAZ with TCS may mitigate the risk of steroid-induced atrophy.
Given the benefits to efficacy and safety with
concurrent use of TCS and TAZ, a fixed-combination HP 0.01%/TAZ 0.045% lotion was
developed to leverage the beneficial properties
of both active ingredients, while mitigating
safety concerns, in a single formulation. The
following sections describe the properties of this
unique formulation and review clinical trials of
HP 0.01%/TAZ 0.045% lotion in the treatment
of psoriasis, with a focus on synergistic efficacy
of HP and TAZ and posttreatment maintenance
of treatment effects.

Fig. 3 Fixed-combination HP 0.01%/TAZ 0.045% lotion
formulation. HP 0.01%/TAZ 0.045% lotion was developed using novel polymeric emulsion technology to
distribute active ingredients and excipients rapidly, efﬁciently, and evenly across the skin. (1) 3-D mesh
(polymeric matrix) holds water and water-soluble hydrating agents. (2) Droplets (1–2 lm) consisting of active
ingredients and oil-soluble moisturizing agents held apart

Polymeric Emulsion-Based Vehicle
Technology
The vehicle used to deliver a topical therapy can
significantly impact the drug’s pharmacokinetics, efficacy, and safety profile [58], as well as
patient adherence to treatment [59]. Thus, in
dermatology, optimization of the topically
applied vehicle represents an opportunity to
maximize therapeutic benefits. The novel formulation for fixed-combination HP 0.01%/TAZ
0.045% lotion utilizes polymeric emulsion
technology that allows active ingredients and
moisturizing excipients to be encapsulated
together within the same oil droplets (Fig. 3)
[14]. These droplets are evenly distributed
throughout a three-dimensional mesh matrix,
which breaks apart upon contact with salts on
the skin to provide more rapid and efficient
delivery of moisturizers, hydrating agents, and
active ingredients into dermal layers than with
the individual ingredients applied either alone
or in layers.
Improved Delivery of Active Ingredients
The improved delivery of active ingredients
with this fixed-combination lotion was
demonstrated in two percutaneous permeation

by the 3-D mesh. (3) 3-D mesh allows for uniform
distribution of active ingredients and moisturizing agents.
(4) 3-D mesh dissolves instantly upon contact with salts on
skin. (5) Active ingredients and moisturizing/hydrating
agents uniformly absorbed by skin. Figure Ó 2021 Ortho
Dermatologics’ afﬁliated entities. Adapted with permission. HP halobetasol propionate, TAZ tazarotene
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studies [14]. HP 0.01%/TAZ 0.045% lotion
demonstrated higher permeation efficiency of
HP, with 6.8% of the applied dose observed in
dermal levels at 24 h. In comparison, only 3.3%
of the applied dose of HP 0.05% cream was
observed, despite having five times greater
concentration of HP. Similarly, HP 0.01%/TAZ
0.09% lotion yielded higher percutaneous
absorption of TAZ, with dermal levels of 20.8%
of the applied dose at 24 h versus 12.3% with
TAZ 0.1% cream alone [14]. In contrast, when
TAZ 0.1% cream was layered on top of HP
0.05% cream, the permeability of TAZ was
decreased [14]. Moreover, a fixed combination
cream formulation of TAZ plus the TCS
betamethasone dipropionate showed no
improvement in the percutaneous absorption of
either active ingredient relative to its monads
[60]. Thus, the improved permeation efficiency
with HP 0.01%/TAZ 0.045% lotion may be
unique to this polymeric emulsion-based fixedcombination lotion formulation.

ingredients. Oil droplets, humectants, and
emollients work in concert to attract and retain
water content within the stratum corneum
while simultaneously providing an occlusive
barrier to prevent moisture loss [14]. In 30
healthy female participants, vehicle lotion
increased skin moisture content (assessed via
corneometry) and improved skin barrier function (assessed via TEWL) relative to untreated
skin. Significant improvements in corneometry
and TEWL were observed 15 min post-application and persisted through 24 h of follow-up.
Specifically, mean corneometry scores peaked at
15–30 min post-application, with a more than
twofold increase (improvement) from baseline;
mean TEWL scores decreased (improved) from
baseline by approximately half at 8 h post-application [13, 14]. Together, these data demonstrate that HP 0.01%/TAZ 0.045% lotion
provides rapid and sustained increases in skin
moisturization and decreases in water loss over
24 h.

Improved Epidermal Barrier Function
A common feature of psoriasis is loss of epidermal barrier function [3, 61]. Topical treatment with both TCS and TAZ is associated with
adverse effects on the integrity of the stratum
corneum, thus potentially exacerbating the
effect of psoriasis on epidermal barrier functions
[62, 63]. Within a few weeks of treatment initiation with TAZ or other topical retinoids,
patients often experience ‘‘retinoid dermatitis,’’
characterized by erythema, scaling, itching/
burning, and desquamation due to loss of the
stratum corneum [62, 64]. Prolonged TCS usage
may decrease lipid synthesis in the stratum
corneum, thus delaying repair of epidermal
barrier damage due to psoriasis and expediting
the return of disease after cessation of TCS
treatment [63]. Reduction in stratum corneum
barrier function increases transepidermal water
loss (TEWL); this can be mitigated by adjunctive
barrier repair therapies such as moisturizers
[62, 63, 65].
The vehicle formulation for HP 0.01%/TAZ
0.045% lotion—developed to provide enhanced
barrier to the skin—delivers a number of
excipients to augment skin moisturization and
mitigate potential adverse effects of the active

Patient Acceptance
Vehicle formulation impacts not only drug
delivery but also patient acceptance and
adherence to treatment. Patients generally prefer vehicles that are lighter, non-greasy, and
easy to use [66, 67]. These cosmetic characteristics can significantly impact patient acceptance,
treatment
adherence,
real-world
effectiveness, and quality of life [14, 59, 68]. In a
patient perception evaluation of HP 0.01%/TAZ
0.045% lotion vehicle, acceptability of the
vehicle lotion was very high, with 93–100%
responding favorably to questions regarding its
application, feel, aesthetics, and moisturizing/
hydrating properties [14]. Ease of use with this
lotion is supported by the simultaneous delivery
of active ingredients and moisturizers/hydrating agents in one formulation, thus reducing
the need to apply moisturizers separately. Further, the polymeric emulsion lotion formulation has demonstrated increased spreadability
compared to a retinoid cream formulation [69].
Thus, HP 0.01%/TAZ 0.045% lotion provides
efficient delivery of active ingredients in an
easy-to-spread lotion formulation that is aesthetically pleasing to patients.
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Table 1 Clinical trials of HP 0.01%/TAZ 0.045% lotion
Study

Phase 2 [13, 70]

Pooled phase 3a [71]

Long-term phase 3 [73]

Study design

Randomized; double-blind

Randomized; double-blind

Open-label

Treatment duration

8 weeks of once-daily
treatment

8 weeks of once-daily
treatment

8 weeks of once-daily treatment,
followed by treatment in
4-week cycles as neededc

Follow-up

Week 12 (4 weeks
posttreatment)

Week 12 (4 weeks
posttreatment)

Every 4 weeks until week 52

Treatment arms (Nb)

HP/TAZ (59)

HP/TAZ (276)

HP/TAZ (555)

HP (63)

Vehicle (142)

TAZ (59)
Vehicle (31)
Inclusion in all studies required an IGA score of 3 (moderate) or 4 (severe) and affected BSA of 3–12%. In all studies, active
ingredients were delivered in the same lotion vehicle
BSA body surface area, HP halobetasol propionate 0.01% lotion, HP/TAZ halobetasol propionate 0.01% and tazarotene
0.045% lotion, IGA Investigator’s Global Assessment, TAZ tazarotene 0.045% lotion
a
Data pooled from two studies
b
For phase 2 and pooled phase 3 studies, N values represent number of participants in the intent-to-treat population. For
long-term phase 3 study, N value represents all participants treated with HP/TAZ lotion
c
All participants were treated with HP/TAZ lotion once daily for 8 weeks. At week 8, treatment was stopped for
participants who achieved treatment success (IGA 0 = clear or 1 = almost clear); all other participants were treated for an
additional 4 weeks). All participants were re-evaluated at week 12 for improvement (C 1 point decrease from baseline IGA
score). Participants demonstrating improvement continued in the study and were managed in 4-week cycles for up to 1 year.
Participants were evaluated every 4 weeks for treatment success; those achieving success stopped treatment for 4 weeks; those
not experiencing success continued once-daily HP/TAZ lotion for 4 weeks. Maximum continuous exposure allowed was
24 weeks

HP 0.01%/TAZ 0.045% LOTION:
EFFICACY AND SAFETY
IN THE TREATMENT OF PSORIASIS
Efficacy of HP 0.01%/TAZ 0.045% Lotion
The efficacy and safety of HP 0.01%/TAZ
0.045% lotion have been demonstrated in one
phase 2 and two phase 3 randomized, doubleblind clinical trials, and one long-term (52week) open-label phase 3 study (Table 1). In the
phase 2 study, rates of treatment success were
greater for HP 0.01%/TAZ 0.045% lotion versus
HP 0.01% and TAZ 0.045% alone after 8 weeks
of once-daily treatment (Fig. 4); note that both
monads were delivered in the same lotion
vehicle as the fixed-combination treatment

[70]. This efficacy was confirmed in data pooled
from the larger phase 3 studies and in the longterm open-label study [71–73]. HP 0.01%/TAZ
0.045% lotion was also superior to its monads
and to vehicle alone in reducing psoriasis signs
of erythema, plaque elevation, and scaling and
reducing affected BSA [70–72]. Importantly,
post hoc analyses demonstrated that the superiority of HP 0.01%/TAZ 0.045% lotion to
vehicle was consistent across many subgroups
of participants in the phase 3 studies, including
male and female subjects [74] and participants
with skin of color [75], target lesions on the
lower extremities [76], or lower BSA involvement (3–5%) at baseline [77].
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Fig. 4 Treatment successa after 8 weeks of once-daily
treatment with HP 0.01%/TAZ 0.045% lotion (placebocontrolled trials). P \ 0.05 vs HP; àP \ 0.001 vs TAZ;
*P \ 0.001 vs vehicle. aTreatment success was deﬁned as at
least a two-grade reduction in IGA score and a score of 0
(clear) or 1 (almost clear). bData pooled from two studies.
N values represent total number of participants in the
intent-to-treat population for each study. All active
ingredients were delivered in the same lotion vehicle. HP
halobetasol propionate 0.01% lotion, HP/TAZ halobetasol
propionate 0.01% and tazarotene 0.045% lotion, IGA
Investigator’s Global Assessment, TAZ tazarotene 0.045%
lotion
Safety and Tolerability of HP 0.01%/TAZ
0.045% Lotion
In the phase 2 and phase 3 clinical trials and in
the long-term open-label study, HP 0.01%/TAZ
0.045% lotion demonstrated a favorable safety
profile and was well tolerated (Table 2)
[70–72, 78]. The majority of AEs reported were
of mild or moderate severity, and the most
common treatment-related AEs were (contact)
dermatitis, (application site) pruritus, and
application site pain. In the pooled phase 3
studies, greater reductions in the severity of
itching, dryness, and burning/stinging skin
symptoms were achieved with HP 0.01%/TAZ
0.045% than vehicle after 8 weeks of treatment
[72].
Importantly, HP 0.01%/TAZ 0.045% lotion is
associated with low incidence of AEs that are of
greatest concern with HP and TAZ monotherapy. Skin atrophy is one of the most problematic adverse side effects associated with
prolonged TCS use, occurring in up to 5% of
participants in clinical trials of TCS treatment
for psoriasis [79]. Because TCS therapy is limited
to 2–4 weeks [11], there is little data on the

incidence of atrophy with longer-term use. In
the phase 2 and pooled phase 3 clinical trials,
during which participants received 8 weeks of
once-daily HP 0.01%/TAZ 0.045% lotion, incidences of atrophy were rare and generally
resolved by study end [70, 71]. In the long-term
open label study, participants received up to
24 weeks of continuous treatment with HP
0.01%/TAZ 0.045% lotion. Despite this prolonged exposure, peak incidence of atrophy was
low (2.3% at week 8) and declined through
study end. Atrophy was reported as an AE in
only four participants (0.7%) and led to only
one discontinuation [73]. This low rate of atrophy—even with up to 24 weeks of exposure to
HP 0.01%/TAZ 0.045% lotion—may reflect the
mechanism of action of TAZ, as retinoids have
been shown to increase dermal fibroblast number and activity as well as increase production of
collagen and elastin [80, 81].
Irritation-related AEs with TAZ are of concern to both patients and clinicians, and likely
cause some avoidance of TAZ monotherapy for
psoriasis [8]. HP 0.01%/TAZ 0.045% lotion is
associated with lower rates of application-site
AEs relative to TAZ monotherapy, perhaps
owing to the anti-inflammatory actions of HP
[8]. In the phase 2 study, treatment-emergent
AEs (TEAEs) were less frequent through week 8
for HP 0.01%/TAZ 0.045% lotion (33.9%) than
for TAZ alone (46.6%), as were discontinuations
from the study due to an AE (3.4% versus
12.1%; Table 2) [70]. Similar rates of TEAEs and
discontinuations were observed in the pooled
phase 3 studies (35.9% and 6.3%, respectively)
[71]. In the phase 3 studies, the most commonly
reported treatment-related AEs through week 8
with HP 0.01%/TAZ 0.045% lotion were contact
dermatitis (6.3%), application site pain (2.6%),
and pruritus (2.2%); few or no participants
reported erythema (n = 0) or skin irritation
(n = 2) as treatment-related AEs [71]. With
longer-term treatment in the open-label study,
rates of these AEs decreased to less than 1% by
week 36 [73, 78]. In comparison, across six
clinical trials of TAZ monotherapy (0.1% or
0.05%; cream or gel formulations), rates were
similar for contact dermatitis (3–8%) but considerably greater for application site pain
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Table 2 Safety of HP 0.01%/TAZ 0.045% lotion
Pooled phase 3a [13, 71]
(through week 8)

Long-term openlabel [13, 73]
(through week 12)

Study

Phase 2 [13, 70] (through week 8)

Treatment armsb

HP/TAZ HP
TAZ
Vehicle
HP/TAZ
Vehicle
HP/TAZ
(n = 59)
(n = 62)
(n = 58)
(n = 31)
(n = 270)
(n = 140)
(n = 527)

C 1 TEAE, %
Discontinuations
due to AE,
n (%)

33.9

21.0

46.6

22.6

35.9

21.4

42.3

2 (3.4)

0

7 (12.1)

1 (3.2)

17 (6.3)

5 (3.6)

30 (5.7)

Common treatment-related TEAEs (C 2% in any active treatment arm), n (%)
Application site
pain

2 (3.4)

0

5 (8.6)

1 (3.2)

7 (2.6)

1 (0.7)

24 (4.6)

Dermatitisc,d

0

0

1 (1.7)

0

17 (6.3)

0

38 (7.2)

Pruritusc

0

0

4 (6.9)

0

6 (2.2)

4 (2.9)

22 (4.2)

Erythema

1 (1.7)

0

2 (3.4)

0

0

0

5 (0.9)

Folliculitisc

2 (3.4)

0

0

0

5 (1.9)

1 (0.7)

9 (1.7)

c

For long-term open-label study, safety data through week 52 have been published [73, 78]
In all studies, active ingredients were delivered in the same lotion vehicle
AE adverse event, HP halobetasol propionate 0.01% lotion, HP/TAZ halobetasol propionate 0.01% and tazarotene 0.045%
lotion, TAZ tazarotene 0.045% lotion, TEAE treatement-emergent adverse event
a
Data pooled from two studies
b
N values represent number of participants in the safety population
c
Application site TEAEs in phase 2 and long-term open-label studies
d
Contact dermatitis in pooled phase 3 studies

(4–11%), pruritus (11–29%), and erythema
(2–28%) [82].
When participants were stratified by baseline
disease severity, tolerability of HP 0.01%/TAZ
0.045% lotion was greatest among participants
with moderate disease (IGA score of 3, n = 232).
Compared to participants with severe disease at
baseline (IGA score of 4, n = 38), moderate IGA
participants experienced lower treatment-related TEAE rates of application site pain (1.7%
vs 7.9%) and pruritus (1.7% vs 5.3%), though
rates of contact dermatitis were comparable
(moderate, 6.5%; severe, 5.3%) [13]. A similar
pattern was observed when stratifying participants by severity of skin symptoms (burning/

stinging, dryness, and itching). HP 0.01%/TAZ
0.045%-treated participants with moderate/severe symptoms at baseline (severity score
of 2 or 3 on a scale of 0 [none] to 3 [severe]) were
approximately two times more likely than participants with less severe symptoms at baseline
(severity score of 0 [none] or 1 [mild]) to have
moderate/severe symptoms at any postbaseline
timepoint [13].
A limitation in interpretation of safety data
from the clinical trials is that unlike real-world
use, participants were required to apply HP
0.01%/TAZ 0.045% lotion once daily for eight
continuous weeks, regardless of treatment
response [71, 72]. As such, it is possible that

Dermatol Ther (Heidelb)

continuing treatment beyond achievement of
treatment success or clearance of psoriasis may
have contributed to irritation. In the clinic,
patient education and a nuanced approach to
treatment may help ameliorate irritation-related AEs, particularly because the prescribing
information for HP 0.01%/TAZ 0.045% lotion
does not provide a minimum or maximum
duration of continuous treatment [83]. Clinicians may want to educate patients on the
importance of minimizing treatment after
achievement of clear skin and avoiding the
overuse of HP 0.01%/TAZ 0.045% lotion. For
individuals experiencing irritation, it is the
authors’ opinion that patients should be
advised to temporarily interrupt drug use (i.e.,
drug holiday) until irritation signs and symptoms have subsided. The authors also recommend encouraging the use of moisturizers—
which are recommended for use with TCS [5]—
concurrent with treatment and/or during periods of irritation-related treatment cessation, to
enhance epidermal barrier function.
Synergistic Efficacy of HP and TAZ
Concurrent use of two complementary active
ingredients often provides a cumulative or
additive effect. In rarer cases, a synergistic effect
is seen wherein the efficacy of the combination
is greater than the summed efficacy of the
individual ingredients. In the phase 2 study, the
treatment success rate of HP 0.01%/TAZ 0.045%
lotion was measured against HP alone, TAZ
alone, and vehicle. Thus, relative efficacy could
be assessed using the ratio of the benefit of HP
0.01%/TAZ 0.045% divided by the summed
benefits of HP and TAZ alone; synergy of HP
0.01%/TAZ 0.045% lotion would thus be
demonstrated by a ratio greater than 1.0 [84]. A
synergistic effect on treatment success was
observed as early as week 2, at which point
treatment benefit of HP 0.01%/TAZ 0.045%
lotion was 11.9%, compared to 6.5% for HP ?
TAZ (ratio of 1.8) [85]. This effect continued
through week 8 of treatment (HP 0.01%/TAZ
0.045%: 42.8%; HP ? TAZ: 32.5%; ratio of 1.3)
and 4 weeks posttreatment (ratio of 1.6). A
similar pattern was observed for reductions

from baseline BSA [85]. This apparent synergy of
HP 0.01%/TAZ 0.045% lotion could result from
the combination of the complementary antiinflammatory and antiproliferative mechanisms
of HP and TAZ. Notably, a fixed-combination
formulation of the vitamin D analogue calcipotriene plus the mid-strength corticosteroid
betamethasone dipropionate (Cal/BD), though
also more efficacious than its monads [5], has
not demonstrated synergistic efficacy beyond
the additive effects of the individual active
ingredients.
Maintenance of Effect After Treatment
Cessation
Among the benefits of TAZ in psoriasis therapy
is a prolonged duration of remission after
treatment cessation. In a clinical trial of TAZ
monotherapy, significantly greater clinical success rate for TAZ versus vehicle was maintained
for 12 weeks after cessation of TAZ treatment
[86]. This maintenance of effect was also
observed in a clinical trial of TAZ used in conjunction with a TCS. After 12 weeks of treatment, TAZ plus TCS was superior to TCS alone
in global improvements as well as individual
signs of psoriasis, and this superiority was
maintained throughout a 12-week posttreatment follow-up period [51]. This prolongation
of therapeutic effect may be due to TAZ
returning skin to a normalized, ‘‘pre-lesional’’
state [15]. In clinical trials of HP 0.01%/TAZ
0.045% lotion, the majority of participants who
achieved treatment success also experienced
prolonged maintenance of the therapeutic
effect after treatment cessation. In the pooled
phase 3 clinical trials, 63% of participants who
achieved treatment success at week 8 remained
treatment successes 4 weeks posttreatment, and
three-quarters of participants maintained or
improved their reductions in affected BSA [87].
Consistent with observations from these
studies, the majority of participants in the longterm open-label study experienced durable
therapeutic effects after cessation of HP 0.01%/
TAZ 0.045% treatment. In this 1-year study,
maintenance of treatment success endured for
over 1 month in approximately 55% of
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Fig. 5 Maintenance of treatment success with HP 0.01%/
TAZ 0.045% lotion (open-label long-term phase 3 study
[73, 88]). Data shown for participants enrolled post
8 weeks in the study and who stopped therapy after
achieving treatment success, deﬁned as an IGA score of 0
(clear) or 1 (almost clear). Cumulative data shown.
‘[ 3 months’’ includes participants who did not relapse
or require any retreatment for the duration of the study;
‘[ 1 month’’ includes participants who did not require
retreatment for [ 3 months or who did not relapse or
require any retreatment for the duration of the study. HP/
TAZ halobetasol propionate 0.01% and tazarotene
0.045%, IGA Investigator’s Global Assessment
participants who stopped treatment after
achieving treatment success, and 6.6% did not
experience any posttreatment relapse for the
duration of the study (Fig. 5) [73]. One important consideration with this finding is that
participants were required to stop treatment
upon achievement of treatment success, defined
as achievement of ‘‘clear’’ or ‘‘almost clear’’ skin.
As such, duration of posttreatment maintenance of effect may have been greater if all
participants had been allowed to continue
treatment until achieving clear skin. This is
supported by an analysis demonstrating that
over 80% of participants who achieved clear
skin did not require retreatment for over
1 month and almost 30% did not require any
retreatment for the duration of the study (Fig. 5)
[88]. These results highlight the importance of
treating to clear skin, which also reflects patient
and clinician goals in a real-world setting.

CONCLUSION
Psoriasis is a chronic disease that frequently
recurs after cessation of treatment, highlighting

the need for therapies that provide rapid,
robust, and lasting results while minimizing
safety concerns and burden of use. HP 0.01%/
TAZ 0.045% lotion is the only topical fixedcombination corticosteroid/tazarotene formulation approved for the treatment of psoriasis
[89]. The complementary mechanisms of action
of TAZ and HP, along with simultaneous delivery of moisturizers and hydrating agents, yields
improvements in efficacy, prolonged duration
of remission, and reductions in safety concerns
with HP 0.01%/TAZ 0.045% lotion over
monotherapy with either active ingredient, and
support its use in the long-term management of
psoriasis.
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